Aprogen pharmaceuticals,Inc. (003060.KS)
KRW 704.0
(-4.22%)
KRW 704.0
(-4.22%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -12.04 Billion KRW | -144.15% |
| 2022 | 27.28 Billion KRW | 7.24% |
| 2021 | 25.44 Billion KRW | 9.67% |
| 2020 | 23.2 Billion KRW | 12.85% |
| 2019 | 20.55 Billion KRW | 9.47% |
| 2018 | 18.78 Billion KRW | -0.27% |
| 2017 | 18.83 Billion KRW | 1.11% |
| 2016 | 18.62 Billion KRW | 23.49% |
| 2015 | 15.08 Billion KRW | 38.93% |
| 2014 | 10.85 Billion KRW | 28.7% |
| 2013 | 8.43 Billion KRW | -18.5% |
| 2012 | 10.35 Billion KRW | -58.21% |
| 2011 | 24.76 Billion KRW | 154.04% |
| 2010 | 9.74 Billion KRW | -67.88% |
| 2009 | 30.35 Billion KRW | 381.37% |
| 2008 | 6.3 Billion KRW | -19.38% |
| 2007 | 7.82 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 169.58 Million KRW | -81.32% |
| 2024 Q1 | 907.62 Million KRW | 120.0% |
| 2023 Q2 | -449.7 Million KRW | -105.9% |
| 2023 Q3 | -3.15 Billion KRW | -601.75% |
| 2023 Q4 | -4.53 Billion KRW | -43.82% |
| 2023 FY | -12.04 Billion KRW | -144.15% |
| 2023 Q1 | 7.62 Billion KRW | 10.77% |
| 2022 FY | 27.28 Billion KRW | 7.24% |
| 2022 Q3 | 6.65 Billion KRW | -1.93% |
| 2022 Q4 | 6.87 Billion KRW | 3.36% |
| 2022 Q2 | 6.78 Billion KRW | -2.53% |
| 2022 Q1 | 6.96 Billion KRW | 6.76% |
| 2021 Q1 | 5.24 Billion KRW | -7.05% |
| 2021 Q2 | 6.88 Billion KRW | 31.25% |
| 2021 Q3 | 6.79 Billion KRW | -1.22% |
| 2021 FY | 25.44 Billion KRW | 9.67% |
| 2021 Q4 | 6.52 Billion KRW | -4.05% |
| 2020 Q2 | 5.7 Billion KRW | -3.23% |
| 2020 FY | 23.2 Billion KRW | 12.85% |
| 2020 Q4 | 5.64 Billion KRW | -5.21% |
| 2020 Q3 | 5.95 Billion KRW | 4.22% |
| 2020 Q1 | 5.9 Billion KRW | -7.72% |
| 2019 Q3 | 4.68 Billion KRW | -6.65% |
| 2019 FY | 20.55 Billion KRW | 9.47% |
| 2019 Q2 | 5.01 Billion KRW | 12.49% |
| 2019 Q1 | 4.46 Billion KRW | -13.5% |
| 2019 Q4 | 6.39 Billion KRW | 36.46% |
| 2018 Q3 | 4.52 Billion KRW | 1.63% |
| 2018 FY | 18.78 Billion KRW | -0.27% |
| 2018 Q1 | 4.64 Billion KRW | -2.64% |
| 2018 Q2 | 4.45 Billion KRW | -4.25% |
| 2018 Q4 | 5.15 Billion KRW | 14.02% |
| 2017 Q2 | 4.41 Billion KRW | -12.65% |
| 2017 Q3 | 4.58 Billion KRW | 3.83% |
| 2017 FY | 18.83 Billion KRW | 1.11% |
| 2017 Q1 | 5.05 Billion KRW | -2.11% |
| 2017 Q4 | 4.77 Billion KRW | 4.13% |
| 2016 FY | 18.62 Billion KRW | 23.49% |
| 2016 Q1 | 4.42 Billion KRW | 3.89% |
| 2016 Q4 | 5.16 Billion KRW | 17.16% |
| 2016 Q3 | 4.4 Billion KRW | -4.78% |
| 2016 Q2 | 4.62 Billion KRW | 4.67% |
| 2015 Q2 | 3.62 Billion KRW | -2.02% |
| 2015 Q3 | 3.5 Billion KRW | -3.27% |
| 2015 FY | 15.08 Billion KRW | 38.93% |
| 2015 Q4 | 4.25 Billion KRW | 21.49% |
| 2015 Q1 | 3.69 Billion KRW | 34.87% |
| 2014 Q2 | 2.82 Billion KRW | 34.02% |
| 2014 Q3 | 3.17 Billion KRW | 12.41% |
| 2014 FY | 10.85 Billion KRW | 28.7% |
| 2014 Q1 | 2.1 Billion KRW | 121.56% |
| 2014 Q4 | 2.74 Billion KRW | -13.73% |
| 2013 Q4 | 952.15 Million KRW | -60.49% |
| 2013 Q3 | 2.4 Billion KRW | -16.74% |
| 2013 FY | 8.43 Billion KRW | -18.5% |
| 2013 Q1 | 2.17 Billion KRW | -24.74% |
| 2013 Q2 | 2.89 Billion KRW | 32.84% |
| 2012 Q4 | 2.89 Billion KRW | -8.18% |
| 2012 Q1 | 2.86 Billion KRW | 0.0% |
| 2012 Q2 | 1.17 Billion KRW | -58.9% |
| 2012 Q3 | 3.15 Billion KRW | 167.37% |
| 2012 FY | 10.35 Billion KRW | -58.21% |
| 2011 Q1 | 6.99 Billion KRW | 0.0% |
| 2011 Q2 | 5.93 Billion KRW | -15.16% |
| 2011 Q3 | 4.74 Billion KRW | -20.15% |
| 2011 FY | 24.76 Billion KRW | 154.04% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q3 | - KRW | -100.0% |
| 2010 Q1 | 6.74 Billion KRW | 0.73% |
| 2010 FY | 9.74 Billion KRW | -67.88% |
| 2010 Q2 | 8.18 Billion KRW | 21.44% |
| 2009 FY | 30.35 Billion KRW | 381.37% |
| 2009 Q3 | - KRW | -100.0% |
| 2009 Q1 | 5.58 Billion KRW | 49.37% |
| 2009 Q2 | 6.11 Billion KRW | 9.41% |
| 2009 Q4 | 6.69 Billion KRW | 0.0% |
| 2008 Q4 | 3.74 Billion KRW | 0.0% |
| 2008 Q3 | - KRW | -100.0% |
| 2008 FY | 6.3 Billion KRW | -19.38% |
| 2008 Q2 | 1.51 Billion KRW | -20.97% |
| 2008 Q1 | 1.92 Billion KRW | -19.48% |
| 2007 Q3 | 1.86 Billion KRW | -10.08% |
| 2007 Q2 | 2.07 Billion KRW | 12.19% |
| 2007 Q1 | 1.84 Billion KRW | 0.0% |
| 2007 FY | 7.82 Billion KRW | 0.0% |
| 2007 Q4 | 2.38 Billion KRW | 28.06% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | 125.902% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 103.308% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 106.057% |
| HANDOK Inc. | 151.36 Billion KRW | 107.958% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | 117.918% |
| Yuhan Corporation | 564.5 Billion KRW | 102.134% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 103.738% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | 150.725% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 101.441% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | 116.052% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 106.054% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | 129.633% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | 112.745% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | 108.552% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | 125.902% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | 134.698% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | 115.681% |
| JW Holdings Corporation | 446.15 Billion KRW | 102.7% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 105.804% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 101.838% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 103.589% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 115.321% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | 116.01% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | 116.681% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | 106.553% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | 125.902% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 104.082% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 101.767% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 103.589% |
| Yuhan Corporation | 564.5 Billion KRW | 102.134% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 105.968% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | 116.98% |
| Suheung Co., Ltd. | 99.02 Billion KRW | 112.164% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 103.589% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | 108.257% |
| Korea United Pharm Inc. | 173.48 Billion KRW | 106.943% |
| CKD Bio Corp. | 5.01 Billion KRW | 340.417% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 104.738% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | 106.542% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | 112.276% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 115.321% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 103.242% |
| Boryung Corporation | 333.26 Billion KRW | 103.614% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | 124.069% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 106.054% |
| JW Lifescience Corporation | 51.32 Billion KRW | 123.469% |